For decades, a diagnosis of Huntington's disease meant one thing: slow, inevitable decline, with no treatment capable of changing the outcome. Every person who received it watched what was coming — memory loss, loss of motor control, personality changes, then death — knowing medicine had nothing to offer except managing symptoms.
That has changed.
**What Huntington's Disease Does**
Huntington's is a hereditary neurological condition caused by a mutation in the HTT gene that produces an abnormal protein, which accumulates in brain cells and progressively destroys them. It typically strikes in mid-life — in a person's 30s, 40s, or 50s — and is universally fatal. There is no approved treatment that slows its progression. Around 30,000 Americans and 8,000 people in the UK live with it; tens of thousands more know they carry the gene and face a future with it.
For families affected by Huntington's, each year without a breakthrough has felt like a year lost.
**The Trial: One Injection, Three Years, Remarkable Results**
AMT-130, developed by the biotech company uniQure, is a gene therapy delivered through a single one-time injection directly into the brain. It uses a harmless virus (AAV5) as a vehicle to deliver a microRNA sequence that silences the mutant HTT gene — targeting the faulty instruction before it can cause damage.
In a small-scale Phase 1/2 clinical trial reported in March 2026, patients receiving the higher dose of AMT-130 showed **75-80% less disease progression** compared to natural history controls after three years. Cognitive function declined more slowly. Motor function declined more slowly. The disease's characteristic march through the brain appeared to be substantially slowed.
For a disease that had never responded to any disease-modifying treatment, 'remarkable' is the word researchers reached for — and it is not an overstatement.
**The UK's Role**
The trial's progress was supported in part by adaptive science advice from the UK's Medicines and Healthcare products Regulatory Agency (MHRA), which worked with uniQure to design the trial in a way that could generate meaningful data from a small number of patients quickly. This kind of regulatory collaboration — science-forward, flexible, and focused on enabling rather than blocking — is increasingly recognised as critical for rare disease innovation.
**What Comes Next**
AMT-130 is still in early trials. A Phase 2/3 trial — with more patients, longer follow-up, and the statistical power to confirm what the Phase 1/2 data suggests — is the next step. If those results hold, the path toward regulatory approval begins.
The timeline is years, not months. For the people currently living with Huntington's, that is a painful reality. But the direction of travel has changed fundamentally. What was once a disease with no hope of treatment now has a treatment that genuinely works in early evidence.
Families who have watched loved ones decline — who have waited through years of promising leads that led nowhere — called the results 'the first genuine hope we have felt.'
It is not a cure. But it is a beginning. And for the Huntington's community, after decades of waiting, a beginning is everything. 🧬
*Sources: uniQure · UK MHRA · HudsonAlpha Institute for Biotechnology · Huntsville Business Journal (March 2026)*
